Clinical Trial Update: A Study to Evaluate Multimodal Neuroimaging Parameters in Women With Postpartum Depression Who Are Receiving ZULRESSO™ (Brexanolone) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating multimodal neuroimaging in postpartum depression using ZULRESSO (brexanolone) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postpartum Depression

Drugs mentioned

• Zulresso (brexanolone)

Snippet

Sponsor: Sage Therapeutics | Conditions: Postpartum Depression | Phase 4 | Status: WITHDRAWN